Back to UBS Group AG UBS Group AG

CLYMCLYM
Showing 8 of 17 quarters

Position history for UBS Group AGUBS Group AG's holdings in CLIMB BIO INC

Yes. Ubs holds 3,404,866 shares of CLYM (Climb Bio), worth $44.4M, as of its Q2 2026 13F filing. It increased the position from 85,945 shares in Q1 2026. Ubs has held CLYM since Q1 2024, across 10 quarterly 13F filings.

Current Value

$44.4M

Current Shares

3.4M

Total Value Change

+$44.3M

Total Shares Change

+3.4M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
3.4M
+3861.7%
$44.4M0.0%$13.04
47
2026-Q1
Increased
85,945
+20.5%
$588,7230.0%$6.85
29
2025-Q4
Decreased
71,323
-82.4%
$285,2920.0%$4.00
0
2025-Q3
Increased
405,404
+6.0%
$814,8620.0%$2.01
26
2025-Q2
Increased
382,482
+0.1%
$474,2780.0%$1.24
24
2025-Q1
Decreased
382,225
-8.0%
$466,3140.0%$1.22
0
2024-Q4
Increased
415,355
+2456.5%
$747,6390.0%$1.80
40
2024-Q3
Increased
16,247
+632.5%
$82,6970.0%$5.09
24

Other major holders of CLYM: RA CAPITAL MANAGEMENT, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used